Advertisement

Current Fungal Infection Reports

, Volume 12, Issue 2, pp 66–70 | Cite as

Fungal Eye Infections: New Hosts, Novel Emerging Pathogens but No New Treatments?

  • Christina C. Chang
  • Sharon C-A Chen
Advances in Diagnosis of Invasive Fungal Infections (S Chen, Section Editor)
  • 90 Downloads
Part of the following topical collections:
  1. Topical Collection on Advances in Diagnosis of Invasive Fungal Infections

Abstract

Purpose of Review

We sought to explore the current incidence and associated risk factors associated with fungal eye infections. We also reviewed new diagnostic strategies and recent clinical studies exploring the use of topical and oral antifungal agents.

Recent Findings

Incidence and associated risks continue to vary with geographic region, and access to timely healthcare. Nosocomial fungal endophthalmitis can result from minor surgical procedures to the eye. Molecular methods offer increasing diagnostic utility. Clinical treatment studies have mainly focussed on the treatment of fungal keratitis and have been conducted in South Asia. Topical natamycin remains superior to topical reconstituted voriconazole and remains the preferred therapy including for Fusarium eye infections. Neither adjunctive oral ketoconazole nor oral voriconazole has been shown to have added clear benefit to topical treatment.

Summary

Larger international studies with more heterogenous populations are required for future clinical studies which should include patients with contact lens fungal keratitis and those with fungal endophthalmitis. Basic science studies exploring the immunology of fungal eye infections and drug levels to understand the differences in clinical outcomes are encouraged.

Keywords

Fungal keratitis Fungal endophthalmitis Invasive fungal infection Contact lens infection Topical natamycin Voriconazole Mycotic ulcer 

Notes

Compliance with Ethical Standards

Conflict of Interest

Christina C. Chang declares no conflict of interest. Sharon C-A Chen has received grant funding from MSD (AUS).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Lalitha P, Prajna NV, Manoharan G, Srinivasan M, Mascarenhas J, Das M, et al. Trends in bacterial and fungal keratitis in South India, 2002-2012. Br J Ophthalmol. 2015;99(2):192–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Aruljyothi L, Radhakrishnan N, Prajna VN, Lalitha P. Clinical and microbiological study of paediatric infectious keratitis in South India: a 3-year study (2011-2013). Br J Ophthalmol. 2016;100(12):1719–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Durand ML. Bacterial and fungal endophthalmitis. Clin Microbiol Rev. 2017;30(3):597–613.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Schimel AM, Miller D, Flynn HW Jr. Endophthalmitis isolates and antibiotic susceptibilities: a 10-year review of culture-proven cases. Am J Ophthalmol. 2013;156(1):50–2. e1CrossRefPubMedGoogle Scholar
  5. 5.
    Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367(23):2194–203.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kauffman CA, Pappas PG, Patterson TF. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med. 2013;368(26):2495–500.CrossRefPubMedGoogle Scholar
  7. 7.
    Edison LS, Dishman HO, Tobin-D’Angelo MJ, Allen CR, Guh AY, Drenzek CL. Endophthalmitis outbreak associated with repackaged bevacizumab. Emerg Infect Dis. 2015;21(1):171–3.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88–93.CrossRefPubMedGoogle Scholar
  9. 9.
    Forooghian F, Albiani DA, Kirker AW, Merkur AB. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept. Can J Ophthalmol. 2017;52(6):616–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Al-Rashaed S, et al. Incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor: experience in Saudi Arabia. Middle East Afr J Ophthalmol. 2016;23(1):60–3.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wani VB, al-Kandari J, Sabti K, Aljassar F, Qali H, Kumar N, et al. Incidence of endophthalmitis after intravitreal bevacizumab using aliquots prepared on-site in 2 operating rooms in Kuwait. Middle East Afr J Ophthalmol. 2016;23(1):64–70.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sheyman AT, Cohen BZ, Friedman AH, Ackert JM. An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. JAMA Ophthalmol. 2013;131(7):864–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Tirpack AR, Duker JS, Baumal CR. An outbreak of endogenous fungal endophthalmitis among intravenous drug abusers in New England. JAMA Ophthalmol. 2017;135(6):534–40.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen SC, Sorrell TC, Chang CC, Paige EK, Bryant PA, Slavin MA. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J. 2014;44(12b):1315–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Weinstein AJ, Johnson EH, Moellering RC Jr. Candida endophthalmitis: a complication of candidemia. Arch Intern Med. 1973;132(5):749–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Kehrmann J, Chapot V, Buer J, Rating P, Bornfeld N, Steinmann J. Diagnostic performance of blood culture bottles for vitreous culture compared to conventional microbiological cultures in patients with suspected endophthalmitis. Eur J Clin Microbiol Infect Dis. 2018;Google Scholar
  18. 18.
    Mehta M, Rasheed RA, Duker J, Reichel E, Feinberg E, Husain D, et al. Vitreous evaluation: a diagnostic challenge. Ophthalmology. 2015;122(3):531–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Li Z, Breitwieser FP, Lu J, Jun AS, Asnaghi L, Salzberg SL, et al. Identifying corneal infections in formalin-fixed specimens using next generation sequencing. Invest Ophthalmol Vis Sci. 2018;59(1):280–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013;131(4):422–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sharma S, Das S, Virdi A, Fernandes M, Sahu SK, Kumar Koday N, et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol. 2015;99(9):1190–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Rajaraman R, Bhat P, Vaidee V, Maskibail S, Raghavan A, Sivasubramaniam S, et al. Topical 5% natamycin with oral ketoconazole in filamentous fungal keratitis: a randomized controlled trial. Asia Pac J Ophthalmol (Phila). 2015;4(3):146–50.CrossRefGoogle Scholar
  23. 23.
    Prajna NV, Krishnan T, Rajaraman R, Patel S, Srinivasan M, Das M, et al. Effect of oral voriconazole on fungal keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): a randomized clinical trial. JAMA Ophthalmol. 2016;134(12):1365–72.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    FlorCruz NV, Evans JR, Medical interventions for fungal keratitis. Cochrane Database Syst Rev, 2015(4): p. CD004241.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Infectious Diseases, Alfred HospitalMonash UniversityMelbourneAustralia
  2. 2.Marie Bashir Institute for Emerging Infectious Diseases and BiosecurityUniversity of SydneySydneyAustralia
  3. 3.Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR, New South Wales Health PathologyWestmead HospitalWestmeadAustralia

Personalised recommendations